Spinal muscular atrophy in the UK: the human toll of slow decisions
Authors:
- 20 February 2025
- journal article
- Published by Elsevier in The Lancet
- Vol. 405 (10479) , 619-620
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Treatment of spinal muscular atrophyCurrent Opinion in Pediatrics, 2024
- Spinal Muscular Atrophy Update in Best PracticesNeurology Clinical Practice, 2024
- 2024 update: European consensus statement on gene therapy for spinal muscular atrophyEuropean Journal of Paediatric Neurology, 2024
- Clinical Effectiveness of Newborn Screening for Spinal Muscular AtrophyJAMA Pediatrics, 2024
- Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening—A Systematic ReviewGenes, 2023
- Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in EnglandNeurology and Therapy, 2023
- Successful integration of newborn genetic testing into UK routine screening using prospective consent to determine eligibility for clinical trialsArchives of Disease in Childhood, 2022
- Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screeningDevelopmental Medicine & Child Neurology, 2022
- Three years pilot of spinal muscular atrophy newborn screening turned into official program in Southern BelgiumScientific Reports, 2021